Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies
In mRCC patients treated with IO and TKI in combination/sequence, subsequent LOT choice is diverse, with TKI-based treatments being the most preferred. There is a need for considering treatment sequencing studies and studies with a new mode of action in this population.
Authors
- Reshma Shinde (ORCID: https://orcid.org/0000-0001-5709-1976)
- Manojkumar Bupathi (ORCID: https://orcid.org/0009-0003-5613-3283)
- Donna Vickery
- Neil J. Shah (ORCID: https://orcid.org/0000-0001-5752-6212)
- Robert John Motzer (ORCID: https://orcid.org/0000-0001-6925-2327)
- Rodolfo F. Perini (ORCID: https://orcid.org/0009-0002-4400-5260)
- Junxin Shi
- Sneha Sura
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3390/cancers17091434
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52